This content is from: Home

Politicians urge Obama to allow public review of IP provisions in TPP

Six members of US Congress have written to US President Barack Obama expressing concern that "secret" negotiations over intellectual property in the Trans Pacific Partnership (TPP) Agreement benefit pharmaceutical companies at the expense of public health.

The six Democrats - Jan Schakowsky (Illonois), Michael Michaud (Maine), Rosa DeLauro (Conneticut), George Miller (California), Barbara Lee (California) and Peter Welch (Vermont) - said the current proposals would have "profound and long-lasting consequences".

In the letter, sent yesterday, the Members urged Obama not to make any final trade agreements "that affect critical health issues" until members of the public and Congress have had the opportunity to review the provisions and provide input.

In particular, they argued that proposed provisions relating to data exclusivity, patent registration and procedure and enforcement would "delay generic competition and increase the price of medicine" and lead to "preventable illnesses and deaths".

"Certainly, trade negotiations conducted behind closed doors are not the place to make changes that would have such profound consequences for patents and veterans, as well as state and federal budgets," they wrote.

Although the TPP negotiations were meant to have been conducted in secret, whistleblowing website WikiLeaks has released several documents which suggest the US is exerting "great pressure" on other nations to adopt stricter IP policies. In the latest release, yesterday, WikiLeaks published two leaked documents that suggest that the US is isolated in its positions on many IP policies.

The material on this site is for law firms, companies and other IP specialists. It is for information only. Please read our Terms and Conditions and Privacy Notice before using the site. All material subject to strictly enforced copyright laws.

© 2020 Euromoney Institutional Investor PLC. For help please see our FAQs.

Related

Instant access to all of our content. Membership Options | One Week Trial